Naxitamab treatment for relapsed or refractory high-risk neuroblastoma: Outcomes from the first prespecified analyses of the Pivotal 201 Trial Meeting Abstract
| Authors: | Mora, J.; Bear, M.; Chan, G.; Morgenstern, D. A.; Nysom, K.; Tornøe, K.; Sørensen, P. S.; Kushner, B. |
| Abstract Title: | Naxitamab treatment for relapsed or refractory high-risk neuroblastoma: Outcomes from the first prespecified analyses of the Pivotal 201 Trial |
| Meeting Title: | ESMO Congress 2022 |
| Journal Title: | Annals of Oncology |
| Volume: | 33 |
| Issue: | Suppl. 7 |
| Meeting Dates: | 2022 Sep 9-13 |
| Meeting Location: | Paris, France |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2022-09-01 |
| Start Page: | S956 |
| Language: | English |
| ACCESSION: | WOS:000866211601162 |
| DOI: | 10.1016/j.annonc.2022.07.1017 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 891P -- Source: Wos |
